Biggest changeThe following table sets forth the components of our results of operations for the periods presented: Twelve months ended Dec. 31, (in thousands) 2024 2023 2022 Net revenues $ 798,894 $ 734,671 $ 631,675 Operating expenses: Revenue share 130,612 158,961 187,670 Marketing and advertising expense 235,696 205,042 207,559 Consumer care and enrollment 222,414 209,234 260,902 Technology expense 41,046 43,302 46,094 General and administrative 82,116 93,069 116,530 Amortization of intangible assets 94,057 94,057 94,057 Operating lease impairment charges — 2,687 25,345 Intangible asset impairment charges — 10,000 — Restructuring and other related charges — — 12,184 Total operating expenses 805,941 816,352 950,341 Income (loss) from operations (7,047) (81,681) (318,666) Interest expense 72,868 69,472 57,069 Gain on bargain purchase (84,492) — — Loss on extinguishment of debt 10,463 — — Other (income) expense, net (834) (37) (115) Income (loss) before income taxes (5,052) (151,116) (375,620) Income tax expense (benefit) 2,267 154 764 Net income (loss) (7,319) (151,270) (376,384) Net income (loss) attributable to noncontrolling interests (4,391) (88,013) (227,678) Net income (loss) attributable to GoHealth, Inc. $ (2,928) $ (63,257) $ (148,706) Non-GAAP financial measures: EBITDA $ 173,706 $ 24,104 $ (211,549) Adjusted EBITDA $ 120,319 $ 75,091 $ (129,776) Net income (loss) margin (0.9) % (20.6) % (59.6) % Adjusted EBITDA margin 15.1 % 10.2 % (20.5) % The following is our net revenues and results thereof for the twelve months ended December 31, 2024 and 2023: Net revenues Twelve months ended Dec. 31, 2024 2023 $ Change % Change $ 798,894 $ 734,671 $ 64,223 8.7 % The $64.2 million, or 8.7% increase compared to the prior year period was primarily attributable to an increase in agency revenue driven by an increase in Submissions for which GoHealth is the agent of record, partially offset by a decrease in non-agency revenue.
Biggest changeThe following table sets forth the components of our results of operations for the periods presented: Twelve months ended Dec. 31, (in thousands) 2025 2024 2023 Net revenues $ 361,845 $ 798,894 $ 734,671 Operating expenses: Revenue share 96,126 130,612 158,961 Marketing and advertising 116,379 235,696 205,042 Consumer care and enrollment 106,045 222,414 209,234 Technology 34,904 41,046 43,302 General and administrative 90,789 82,116 93,069 Amortization of intangible assets 70,542 94,057 94,057 Indefinite and long-lived asset impairment charges 259,961 — 12,687 Total operating expenses 774,746 805,941 816,352 Income (loss) from operations (412,901) (7,047) (81,681) Interest expense 87,320 72,868 69,472 Gain on bargain purchase — (84,492) — Loss on extinguishment of debt 1,655 10,463 — Other (income) expense, net (786) (834) (37) Income (loss) before income taxes (501,090) (5,052) (151,116) Income tax expense (benefit) (3,335) 2,267 154 Net income (loss) (497,755) (7,319) (151,270) Net income (loss) attributable to noncontrolling interests (240,629) (4,391) (88,013) Net income (loss) attributable to GoHealth, Inc. $ (257,126) $ (2,928) $ (63,257) Non-GAAP financial measures: EBITDA $ (333,664) $ 173,706 $ 24,104 Adjusted EBITDA $ (35,109) $ 120,319 $ 75,091 Net income (loss) margin (137.6) % (0.9) % (20.6) % Adjusted EBITDA margin (9.7) % 15.1 % 10.2 % The following is our net revenues and results thereof for the twelve months ended December 31, 2025 and 2024: Net revenues Twelve months ended Dec. 31, 2025 2024 $ Change % Change $ 361,845 $ 798,894 $ (437,049) (54.7) % The $437.0 million, or 54.7% decrease compared to the prior year period was primarily attributable to the scale back of our Medicare Advantage activities in response to tightening health plan economics, partially offset by the launch of GoHealth Protect during the second quarter of 2025.
The decrease was partially offset by an increase in cash from working capital components from prepaid assets and other current assets and commissions payable, as well as an increase in net income (loss).
The decrease was partially offset by an increase in cash from working capital components from prepaid assets and other current assets and commissions payable, as well as an decrease in net income (loss).
See “Risk Factors—Risks Related to Our Business—Our operating results may be adversely impacted by factors that impact our estimate of LTV” in this Annual Report on Form 10-K. Agency revenue includes partner marketing revenue, in which the Company is compensated by its health plan partners for providing marketing services over a predetermined measurement period.
“Risk Factors—Risks Related to Our Business—Our operating results may be adversely impacted by factors that impact our estimate of LTV” in this Annual Report on Form 10-K. Agency revenue includes partner marketing revenue, in which the Company is compensated by its health plan partners for providing marketing services over a predetermined measurement period.
With a widely scalable end-to-end platform and substantial presence in the Medicare landscape, we believe we are uniquely positioned as a trusted partner to the 67 million Medicare-eligible Americans, as well as the 11,000 Americans becoming eligible each day, as they navigate one of life's most important purchasing decisions.
With a widely scalable end-to-end platform and substantial presence in the Medicare landscape, we believe we are uniquely positioned as a trusted partner to the 68 million Medicare-eligible Americans, as well as the 11,000 Americans becoming eligible each day, as they navigate one of life's most important purchasing decisions.
Factors that could cause such differences are discussed in the sections titled “Cautionary Note Regarding Forward-Looking Statements,” “Summary Risk Factors” and “Risk Factors” in this Annual Report on Form 10-K. The risks and uncertainties described in this 2024 Annual Report on Form 10-K are not the only risks and uncertainties we face.
Factors that could cause such differences are discussed in the sections titled “Cautionary Note Regarding Forward-Looking Statements,” “Summary Risk Factors” and “Risk Factors” in this Annual Report on Form 10-K. The risks and uncertainties described in this 2025 Annual Report on Form 10-K are not the only risks and uncertainties we face.
Weakening industry or economic trends, disruptions to our business, changes in discount rate assumptions, unexpected significant changes or planned changes in the use of the assets or in our entity structure are all factors which may adversely impact the assumptions used in the valuation.
Weakening industry or economic trends, disruptions to the Company's business, changes in discount rate assumptions, unexpected significant changes or planned changes in the use of the assets or in the Company’s entity structure are all factors which may adversely impact the assumptions used in the valuation.
The persistency-adjusted renewal period is determined based on our historical experience and available industry and health plan partner historical data. Persistency adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period.
The persistency-adjusted renewal period is determined based on our historical experience and available industry and health plan partner historical data. Persistency adjustments allow us to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period. See Item 1A.
In addition to tax expenses, we also incur expenses related to our status as a public company, plus payment obligations under the Tax Receivable Agreement (“TRA”), which could be significant. We intend to cause GHH, LLC to make distributions to us in an amount sufficient to allow us to pay these expenses and fund any payments due under the TRA.
In addition to tax expenses, we also incur expenses related to our status as a public company, plus payment obligations under the TRA, which could be significant. We intend to cause GHH, LLC to make distributions to us in an amount sufficient to allow us to pay these expenses and fund any payments due under the TRA.
The following discussion and analysis is intended to highlight and supplement data and information presented elsewhere in this Annual Report on Form 10-K, including the Consolidated Financial Statements and related Notes, and should be read in conjunction with the accompanying tables.
The following discussion and analysis is intended to highlight and supplement data and information presented elsewhere in this Annual Report on Form GoHealth, Inc. 2025 Form 10-K 47 10-K, including the Consolidated Financial Statements and related Notes, and should be read in conjunction with the accompanying tables.
Update on Business Trends and Strategy GoHealth has evolved from a traditional Medicare enrollment company to a Medicare engagement company, focusing on forging high-quality relationships with our consumers.
Update on Business Trends and Strategy GoHealth has evolved from a traditional Medicare enrollment company to a Medicare engagement and digital health marketplace focusing on forging high-quality relationships with our consumers.
The accounting policies we believe to reflect our more significant estimates, judgments and assumptions that are most critical to understanding and evaluating our reported financial results are: • Commission revenue recognition and commissions receivable; • Share-based compensation; • Intangible assets; • Impairment of operating lease ROU assets; • Liabilities pursuant to the TRA.
The accounting policies we believe to reflect our more significant estimates, judgments and assumptions that are most critical to understanding and evaluating our reported financial results are: • Commission revenue recognition and commissions receivable; • Share-based compensation; • Intangible assets; and • Liabilities pursuant to the TRA.
The percentage ownership of total shares of Class A and Class B common stock issued and outstanding as of December 31, 2024, is as follows: GoHealth, Inc. 2024 Form 10-K 46 The percentage of ownership noted above is inclusive of only Class A and Class B common stock issued and outstanding.
The percentage ownership of total shares of Class A and Class B common stock issued and outstanding as of December 31, 2025, is as follows: GoHealth, Inc. 2025 Form 10-K 49 The percentage of ownership noted above is inclusive of only Class A and Class B common stock issued and outstanding.
Share-based compensation expense for Time-Vesting Units, RSUs, stock options and PSUs are recognized on a straight-line basis over the requisite service or performance period, which is generally three to five years. We recognize forfeitures as they occur. The fair value of Time-Vesting Units and market-based PSUs are determined using a Monte Carlo simulation.
Share-based compensation expense for Time-Vesting Units, RSUs, stock options and PSUs are recognized on a straight-line basis over the requisite service or performance period, which is generally three to five years. We recognize forfeitures as they occur. GoHealth, Inc. 2025 Form 10-K 59 The fair value of Time-Vesting Units and market-based PSUs are determined using a Monte Carlo simulation.
The enrollment and engagement services offered through our non-agency model are strategically designed to enhance the consumer experience, reflecting our focus on building trusted, long-term relationships with our consumers. Non-agency revenue for the twelve months ended December 31, 2024 represented 27% of total Medicare revenue compared to 38% of total Medicare revenue for the twelve months ended December 31, 2023.
The enrollment and engagement services offered through our non-agency model are strategically designed to enhance the consumer experience, reflecting our focus on building trusted, long-term relationships with our consumers. Non-agency revenue for the twelve months ended December 31, 2025 represented 15% of Total net revenue compared to 27% of Total Net revenue for the twelve months ended December 31, 2024.
As part of this effort, we launched Encompass Express, an enhanced, consumer-centric operating model built on the foundation of our original Encompass workflow. Encompass Express includes streamlined scripting and hand-offs, utilizing technology-driven standardization and automation to deliver efficiency and enhance the consumer experience while maintaining quality.
As part of this effort, we continued to operate under our Encompass Express model which is an enhanced, consumer-centric operating model built on the foundation of our original Encompass workflow. Encompass Express includes streamlined scripting and hand-offs, utilizing technology-driven standardization and automation to deliver efficiency and enhance the consumer experience while maintaining quality.
The following table presents a summary of cash flows for the twelve months ended December 31, 2024, 2023, and 2022; Twelve months ended Dec. 31, (in thousands) 2024 2023 2022 Net cash provided by (used in) operating activities $ (21,607) $ 109,141 $ 60,904 Net cash provided by (used in) investing activities $ 3,807 $ (13,732) $ (13,512) Net cash provided by (used in) financing activities $ (32,033) $ (21,106) $ (115,051) Operating Activities Cash provided by (used in) operating activities primarily consists of net income (loss) adjusted for certain non-cash items including share-based compensation, depreciation and amortization, amortization of intangible assets, amortization of debt discount and issuance costs, intangible impairment charges, loss on extinguishment of debt, operating lease impairment charges, deferred tax liability, non-cash restructuring charges, non-cash lease expense, gain on bargain purchase and the effect of changes in working capital and other activities.
The following table presents a summary of cash flows for the twelve months ended December 31, 2025, 2024, and 2023; Twelve months ended Dec. 31, (in thousands) 2025 2024 2023 Net cash provided by (used in) operating activities $ (121,947) $ (21,607) $ 109,141 Net cash provided by (used in) investing activities $ (8,248) $ 3,807 $ (13,732) Net cash provided by (used in) financing activities $ 121,996 $ (32,033) $ (21,106) Operating Activities Cash provided by (used in) operating activities primarily consists of net income (loss) adjusted for certain non-cash items including share-based compensation, depreciation and amortization, amortization of intangible assets, amortization of debt discount and issuance costs, intangible impairment charges, loss on extinguishment of debt, operating lease impairment charges, deferred tax liability, non-cash restructuring charges, non-cash lease expense, gain on bargain purchase and the effect of changes in working capital and other activities.
GoHealth, Inc. 2024 Form 10-K 47 Results of Operations The following is a discussion and analysis of changes in the financial condition and results of operations for fiscal year 2024 compared to fiscal year 2023.
GoHealth, Inc. 2025 Form 10-K 50 Results of Operations The following is a discussion and analysis of changes in the financial condition and results of operations for fiscal year 2025 compared to fiscal year 2024.
The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. The non-controlling interest holders' weighted average ownership percentages for the twelve months ended December 31, 2024, 2023, and 2022 were 56.2%, 58.2% and 61.1%, respectively.
The weighted average ownership percentages for the applicable reporting periods are used to attribute net income (loss) and other comprehensive income (loss) to the Company and the non-controlling interest holders. The non-controlling interest holders' weighted average ownership percentages for the twelve months ended December 31, 2025, 2024, and 2023 were 49.4%, 56.2% and 58.2%, respectively.
The following are our Submissions, Sales per Submission and Direct Operating Cost per Submission for the periods presented: Twelve months ended Dec. 31, 2024 2023 2022 Submissions 1,016,182 826,159 862,656 Sales per Submission $ 781 $ 866 $ 915 Direct Operating Cost per Submission $ 578 $ 683 $ 747 Submissions GoHealth, Inc. 2024 Form 10-K 51 Submissions are counted when an individual either (i) completes an application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our Non-Encompass BPO Services or (ii) is transferred by our agent to the health plan partner through the Encompass marketplace during the indicated period.
The following are our Submissions, Sales per Submission and Direct Operating Cost per Submission for the periods presented: Twelve months ended Dec. 31, 2025 2024 2023 Submissions 534,657 1,016,182 826,159 Sales per Submission $ 668 $ 781 $ 866 Direct Operating Cost per Submission $ 594 $ 578 $ 683 Submissions Submissions are counted when an individual either (i) completes an application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications GoHealth, Inc. 2025 Form 10-K 54 through our Non-Encompass BPO Services or (ii) is transferred by our agent to the health plan partner through the Encompass marketplace during the indicated period.
A discussion and analysis regarding our results of operations for fiscal year 2023 compared to fiscal year 2022 that are not included in this Annual Report on Form 10-K can be found in our Annual Report on Form 10-K filed with the SEC on March 14, 2024.
A discussion and analysis regarding our results of operations for fiscal year 2024 compared to fiscal year 2023 that are not included in this Annual Report on Form 10-K can be found in our Annual Report on Form 10-K filed with the SEC on February 27, 2025.
The fair values were estimated using a discounted cash flow approach on forecasted future cash flows expected to be derived from the property based on current sublease market rent, which is considered a level 3 input in the fair value hierarchy.
Determination of the fair values of operating lease ROU assets were estimated using a discounted cash flow approach on forecasted future cash flows expected to be derived from the property based on current sublease market rent, which is considered a level 3 input in the fair value hierarchy.
The change was primarily driven by the acquisition of e-TeleQuote, partially offset by an increase in capitalized internal-use software related to new technology, software and systems. Financing Activities Net cash used in financing activities was $32.0 million for the twelve months ended December 31, 2024, from $21.1 million for the twelve months ended December 31, 2023.
The change was primarily driven by the acquisition of e-TeleQuote, partially offset by an increase in capitalized internal-use software related to new technology, software and systems. Financing Activities Net cash provided by financing activities was $122.0 million for the twelve months ended December 31, 2025, from $32.0 million for the twelve months ended December 31, 2024.
The increase was primarily driven by an increase in repayments of our Term Loan Facilities, an increase in payments related to debt issuance costs related to the Amended and Restated Credit Agreement, partially offset by an increase in borrowings under the Revolving Credit Facilities and a decrease in payments of preferred stock dividends compared to the prior year period.
The increase was primarily driven by an increase in repayments of our Term Loan Facilities, an increase in payments related to debt issuance costs related to the Amended and Restated Credit Agreement, GoHealth, Inc. 2025 Form 10-K 57 partially offset by an increase in borrowings under the Revolving Credit Facilities and a decrease in payments of preferred stock dividends compared to the prior year period.
The $130.7 million decrease was primarily driven by a decrease in cash from working capital components from commissions receivable, other liabilities, accounts payable, accounts receivable and accrued liabilities.
The $100.3 million decrease was primarily driven by a decrease in cash from working capital components from commissions receivable, other liabilities, accounts payable, accounts receivable and accrued liabilities.
As of December 31, 2024, the Company had a principal amount of $475.0 million outstanding under the New Term Loan Facility and no principal amounts outstanding under Term Loan Facilities. The effective interest rate of the New Term Loan Facility was 12.06% at December 31, 2024.
As of December 31, 2024, the Company had a principal amount of $475.0 million outstanding under the Term Loan Facilities. The effective interest rate of the Term Loan Facilities was 12.06 at December 31, 2024.
Gain on bargain purchase Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ (84,492) $ — $ (84,492) NM (10.6)% —% NM = Not meaningful We recognized a gain on bargain purchase of $84.5 million for the twelve months ended December 31, 2024 related to the e-TeleQuote acquisition.
GoHealth, Inc. 2025 Form 10-K 52 Gain on bargain purchase Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ — $ (84,492) $ 84,492 NM —% (10.6)% NM = Not meaningful We recognized a gain on bargain purchase of $(84.5) million for the twelve months ended December 31, 2024 related to the e-TeleQuote acquisition.
The Company collectively refers to the Incremental Term Loan Facility, the 2021 Incremental Term Loans and the 2021-2 Incremental Term Loans as the “Term Loan Facilities.” On November 4, 2024 (the “Effective Date”), the Borrower entered into the Amendment and Restatement Agreement, which amended and restated the Credit Agreement to provide for, among other items as further described below, a new class of term loan facilities (the “New Term Loan Facility”) in an aggregate principal amount equal to $475.0 million.
Term Loan Facilities On November 4, 2024 (the “Effective Date”), the Borrower entered into the Amendment and Restatement Agreement, which amended and restated the Credit Agreement to provide for, among other items as further described below, a new class of term loan facilities (the “New Term Loan Facility”) in an aggregate principal amount equal to $475.0 million.
As of December 31, 2024 and December 31, 2023, the Company determined that a $1.1 million and $0.8 million liability related to the Tax Receivable Agreement arose from the Transactions, respectively.
As of December 31, 2025 and December 31, 2024, the Company determined that a $1.3 million and $1.1 million liability related to the Tax Receivable Agreement arose from the Transactions, respectively.
The uncertainty associated with the variable consideration is subsequently resolved when the policy terminates. Commissions receivable includes the variable consideration for policies that may renew, and therefore, are subject to the same assumptions, judgments and estimates used when recognizing commission revenue as noted above. See Note 10, “Revenue,” for further discussion of commission revenue and commissions receivable.
The uncertainty associated with the variable consideration is subsequently resolved when the policy terminates. Commissions receivable includes the variable consideration for policies that may renew, and therefore, are subject to the same assumptions, judgments and estimates used when recognizing commission revenue as noted above.
Investing Activities Net cash provided by investing activities increased to $3.8 million for the twelve months ended December 31, 2024, from $13.7 million net cash used in investing activities for the twelve months ended December 31, 2023.
Investing Activities Net cash used in investing activities increased to $8.2 million for the twelve months ended December 31, 2025, from $3.8 million net cash provided by investing activities for the twelve months ended December 31, 2024.
GoHealth, Inc. 2024 Form 10-K 55 See Note 5, “Long-Term Debt,” to the Consolidated Financial Statements in this Annual Report on Form 10-K for additional information regarding the Company’s Credit Facilities. Seasonality The Medicare annual enrollment period (“AEP”) occurs from October 15 th to December 7 th .
See Note 5, “Long-Term Debt,” to the Consolidated Financial Statements in this Annual Report on Form 10-K for additional information regarding the Company’s Credit Facilities. Seasonality GoHealth, Inc. 2025 Form 10-K 58 AEP occurs from October 15 th to December 7 th .
The shift from non-agency to agency revenue is a result of changing carrier mix within the non-agency channel. The mix of agency and non-agency contracts is dependent on the plans most suitable for the consumers we serve and is impacted by changing market dynamics as further described below. We continue to refine our Encompass operating model through investments in technology.
The shift from non-agency to agency revenue is a result of changing carrier mix within the non-agency channel. The mix of agency and non-agency contracts is dependent on the plans most suitable for the consumers we serve and is impacted by changing market dynamics as further described below.
SARs are liability-classified awards, and as such, are recorded as a liability on the Consolidated Balance Sheets. The assumptions we use represent management's best estimates. If factors change and different assumptions are used, our compensation expense for stock options could be materially different for future grants. See Note 7, “Share-Based Compensation Plans,” for further discussion of share-based compensation.
SARs are liability-classified awards, and as such, are recorded as a liability on the Consolidated Balance Sheets. The assumptions we use represent management's best estimates. If factors change and different assumptions are used, our compensation expense for stock options could be materially different for future grants.
Should the Company determine that any additional Tax Receivable Agreement liability is considered probable at a future date based on new information, any changes will be recorded within earnings at that time. See Note 9, “Income Taxes” for further discussion of the TRA.
Should the Company determine that any additional Tax Receivable Agreement liability is considered probable at a future date based on new information, any changes will be recorded within earnings at that time. See Note 9, “Income Taxes” to the Consolidated Financial Statements included in Item 8 to this Annual Report on Form 10-K for further discussion of the TRA.
Share-Based Compensation GoHealth, Inc. 2024 Form 10-K 56 We grant share-based awards to employees and non-employee directors. Share-based awards include time-vesting profits units (“Time-Vesting Units”), restricted stock units (“RSUs”), stock options, performance stock units (“PSUs”) and stock appreciation rights ("SARs"). We recognize compensation expense for all share-based awards based on the estimated grant date fair value.
Share-based awards include time-vesting profits units (“Time-Vesting Units”), restricted stock units (“RSUs”), stock options, performance stock units (“PSUs”) and stock appreciation rights ("SARs"). We recognize compensation expense for all share-based awards based on the estimated grant date fair value.
The following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods presented: GoHealth, Inc. 2024 Form 10-K 50 Twelve months ended Dec. 31, Non-GAAP Financial Measures 2024 2023 2022 Net revenues $ 798,894 $ 734,671 $ 631,675 Net income (loss) (7,319) (151,270) (376,384) Interest expense 72,868 69,472 57,069 Income tax expense (benefit) 2,267 154 764 Depreciation and amortization expense 105,890 105,748 107,002 EBITDA 173,706 24,104 (211,549) Gain on bargain purchase 1 (84,492) — — Share-based compensation expense 2 11,281 19,564 32,124 Loss on extinguishment of debt 3 10,463 — — Professional services 4 3,671 1,548 4,752 Legal fees 5 2,917 14,840 3,478 Severance costs 6 2,480 1,920 3,340 Other (income) loss related to the adjustment of liabilities under the Tax Receivable Agreement 7 293 428 550 Operating lease impairment charges 8 — 2,687 25,345 Restructuring and other related charges 9 — — 12,184 Intangible asset impairment charges 10 — 10,000 — Adjusted EBITDA $ 120,319 $ 75,091 $ (129,776) Net income (loss) margin (0.9) % (20.6) % (59.6) % Adjusted EBITDA margin 15.1 % 10.2 % (20.5) % (1) Represents the excess of the acquisition-date fair value of the net assets acquired over the acquisition-date fair value of the consideration transferred related to the acquisition of e-TeleQuote, as further described in Note 15, Acquisitions.
The following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods presented: GoHealth, Inc. 2025 Form 10-K 53 Twelve months ended Dec. 31, Non-GAAP Financial Measures 2025 2024 2023 Net revenues $ 361,845 $ 798,894 $ 734,671 Net income (loss) (497,755) (7,319) (151,270) Interest expense 87,320 72,868 69,472 Income tax expense (benefit) (3,335) 2,267 154 Depreciation and amortization expense 80,106 105,890 105,748 EBITDA (333,664) 173,706 24,104 Gain on bargain purchase 1 — (84,492) — Share-based compensation expense 2 9,170 11,281 19,564 Loss on extinguishment of debt 3 1,655 10,463 — Professional services 4 11,463 3,671 1,548 Legal fees 5 5,042 2,917 14,840 Severance costs 6 11,550 2,480 1,920 Other (income) loss related to the adjustment of liabilities under the Tax Receivable Agreement 7 — 293 428 Indefinite and long-lived asset impairment charges 8 259,675 — 12,687 Adjusted EBITDA $ (35,109) $ 120,319 $ 75,091 Net income (loss) margin (137.6) % (0.9) % (20.6) % Adjusted EBITDA margin (9.7) % 15.1 % 10.2 % (1) Represents the excess of the acquisition-date fair value of the net assets acquired over the acquisition-date fair value of the consideration transferred related to the acquisition of e-TeleQuote, as further described in Note 14, Acquisitions.
Net cash used in operating activities was $21.6 million for the twelve months ended December 31, 2024, compared to net cash provided by operating activities of $109.1 million for the twelve months ended December 31, 2023.
Net cash used in operating activities was $121.9 million for the twelve months ended December 31, 2025, compared to net cash used in operating activities of $21.6 million for the twelve months ended December 31, 2024.
The following are our key components of operating expenses and results thereof for the twelve months ended December 31, 2024 and 2023: Revenue share Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 130,612 $ 158,961 $ (28,349) (17.8) % 16.3% 21.6% GoHealth, Inc. 2024 Form 10-K 48 The $28.3 million, or 17.8% decrease was primarily driven by a decrease in Submissions generated by our external agents, which decreased the amount of expense we recognized pursuant to our revenue-sharing agreements with our external partners.
The following are our key components of operating expenses and results thereof for the twelve months ended December 31, 2025 and 2024: Revenue share Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 96,126 $ 130,612 $ (34,486) (26.4) % 26.6% 16.3% The $34.5 million, or 26.4% decrease was primarily driven by a decrease in Submissions generated by our external agents, which decreased the amount of expense we recognized pursuant to our revenue-sharing agreements with our external partners.
As a result, during the twelve months ended December 31, 2023, we recorded an indefinite-lived trade names impairment charge of $10.0 million to write down the carrying value of the indefinite-lived trade names to their fair value of $73.0 million.
As a result, during the twelve months ended December 31, 2023, we recorded an indefinite-lived trade names impairment charge of $10.0 million to write down the carrying value of the indefinite-lived trade names to their fair value which is included in “Indefinite and long-lived asset impairment charges” on the Consolidated Statements of Operations.
As of December 31, 2024 the Company had $30.0 million outstanding under the New Class A Revolving Credit Facility and no amounts outstanding under the Class A-1 Revolving Credit Facility. The New Class A Revolving Credit Facility and Class A-1 Revolving Credit Facility had a remaining capacity of $58.5 million and $35.0 million, respectively, as of December 31, 2024.
As of December 31, 2025 the Company had no outstanding balance under the Class A Revolving Credit Facility and no amounts outstanding under the Class A-1 Revolving Credit Facility. The Company had $30.0 million outstanding under the Class A Revolving Credit Facilities and Class B Revolving Credit Facilities as of December 31, 2024.
After the New Class A Revolving Facility Termination Date, the Class A-1 Revolving Credit Facility will bear interest at either (i) ABR plus 6.25% per annum or (ii) SOFR plus 7.25% per annum. The Borrower is required to pay a commitment fee of 1% per annum on undrawn amounts under the Class A-1 Revolving Credit Facility.
The Class A Revolving Credit Facility bore interest at either (i) ABR plus 5.50% per annum or (ii) SOFR plus 6.50% per annum. The Borrower was required to pay a commitment fee of 0.50% per annum on undrawn amounts under the Class A Revolving Credit Facility.
Additionally, the Company made the strategic decision to exit its Non-Encompass BPO Services, or services in which we dedicate certain agents to specific health plan partners and agencies outside of the Encompass model, to focus on our core business. The exit was completed during the second quarter of 2023.
In the second quarter of 2023, the Company exited its Non-Encompass BPO Services, or services in which we dedicate certain agents to specific health plan partners and agencies outside of the Encompass model, to focus on our core business. During the twelve months ended December 31, 2025, and 2024 Non-Encompass BPO Services contributed no revenues.
For more information on the Company’s agency and non-agency revenue, refer to Note 10, “Revenue.” The following table presents the Sales per Submission for the periods presented: Sales Per Submission Twelve months ended Dec. 31, 2024 2023 $ Change % Change $ 781 $ 866 $ (85) (9.8) % GoHealth, Inc. 2024 Form 10-K 52 The decrease for the twelve months ended December 31, 2024 compared to the prior year period was primarily attributable to a shift from non-agency to agency revenue as a result of changing carrier mix within the non-agency channel.
For more information on the Company’s agency and non-agency revenue, refer to Note 10, “Revenue.” The following table presents the Sales per Submission for the periods presented: Sales Per Submission Twelve months ended Dec. 31, 2025 2024 $ Change % Change $ 668 $ 781 $ (113) (14.5) % The decrease for the twelve months ended December 31, 2025 compared to the prior year period was primarily attributable to a shift in focus to GoHealth Protect.
The following are our Direct Operating Cost of Submission (in thousands) and Sales/Direct Operating Cost of Submission for the periods presented: Twelve months ended Dec. 31, 2024 2023 2022 Direct Operating Cost of Submission $ 587,371 $ 563,552 $ 644,706 Sales/Direct Operating Cost of Submission 1.4 1.3 1.2 The increase in Sales/Direct Operating Cost of Submission compared to the prior year was primarily attributable to improvements in agent productivity through enhanced training programs and investment in our technology.
The following are our Direct Operating Cost of Submission (in thousands) and Sales/Direct Operating Cost of Submission for the periods presented: Twelve months ended Dec. 31, 2025 2024 2023 Direct Operating Cost of Submission $ 317,553 $ 587,371 $ 563,552 Sales/Direct Operating Cost of Submission 1.1 1.4 1.3 The decrease in Sales/Direct Operating Cost of Submission compared to the prior year was primarily attributable to a decrease in sales offset partially by implemented cost cutting initiatives.
Loss on extinguishment of debt Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 10,463 $ — $ 10,463 NM 1.3% —% We recognized a loss on extinguishment of debt of $10.5 million for the twelve months ended December 31, 2024 related to the extinguishment of the Term Loan Facilities.
Loss on extinguishment of debt Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 1,655 $ 10,463 $ (8,808) (84.2) % 0.5% 1.3% We recognized a loss on extinguishment of debt of $1.7 million and $10.5 million for the twelve months ended December 31, 2025 and 2024 pursuant to the Company’s executed debt agreements.
Direct Operating Cost per Submission measures costs directly attributable to Submissions generated in the period and excludes costs that are indirect or fixed.
GoHealth, Inc. 2025 Form 10-K 55 Direct Operating Cost Per Submission Direct Operating Cost per Submission is an operating metric that represents the average performance of Submissions generated during the reporting period. Direct Operating Cost per Submission measures costs directly attributable to Submissions generated in the period and excludes costs that are indirect or fixed.
In connection with our annual indefinite-lived impairment test performed as of November 30, 2023, the Company determined that the fair value of our indefinite-lived trade names no longer exceeded their carrying value.
The Company also recorded impairment charges related to capitalized software, property and equipment and ROU assets of $28.0 million for the twelve months ended December 31, 2025. In connection with our annual indefinite-lived impairment test performed as of November 30, 2023, the Company determined that the fair value of our indefinite-lived trade names no longer exceeded their carrying value.
The following table presents the number of Submissions for the periods presented: Submissions Twelve months ended Dec. 31, 2024 2023 $ Change % Change 1,016,182 826,159 190,023 23.0 % The increase for the twelve months ended December 31, 2024 compared to the prior year period was primarily attributable to an increase in Submissions generated by GoHealth’s internal network of agents, powered by our enhanced marketing efforts, investments in technology and an increased agent headcount as a result of the e-TeleQuote acquisition.
The following table presents the number of Submissions for the periods presented: Submissions Twelve months ended Dec. 31, 2025 2024 $ Change % Change 534,657 1,016,182 (481,525) (47.4) % The decrease for the twelve months ended December 31, 2025 compared to the prior year period was attributable to a decrease in Submissions generated by GoHealth’s internal and external network of agents, partially offset by an increased agent headcount in early 2025 as a result of the e-TeleQuote acquisition and by the ramp up of GoHealth Protect since its launch in the second quarter of 2025.
We believe our end-to-end Encompass model offers a differentiated way for Medicare beneficiaries to navigate the complex Medicare Advantage plan selection process and begin to utilize their new plan benefits with greater confidence. The Encompass operating model supports all Medicare services, including agency and non-agency revenue.
We believe our end-to-end Encompass model offers a differentiated way for Medicare beneficiaries to navigate the complex Medicare Advantage plan selection process and begin to utilize their new plan benefits with greater confidence. In 2025, insurers offering Medicare Advantage plans faced ongoing disruptions affecting their financial performance, driven by rising medical costs and regulatory pressures.
Beginning on March 31, 2025, principal payments equal to 2.00% of the outstanding principal balance per annum of the New Term Loans will be paid in equal quarterly installments. To the extent not previously paid, the New Term Loan Facility, together with all accrued and unpaid interest thereon, is due and payable on November 4, 2029.
To the extent not previously paid, the Existing Term Loan Facility, together with all accrued and unpaid interest thereon, is due and payable on November 4, 2029.
Determination of fair value involves utilizing the relief-from-royalty under the income approach which contains significant estimates and assumptions including, among others, revenue projections as well as selecting appropriate royalty and discount rates. While we believe the judgments and assumptions are reasonable, different assumptions could change the estimated fair value and, therefore, additional impairments could be required.
There were no impairment charges in 2024. Determination of fair value of the trade name involves utilizing the relief-from-royalty under the income approach which contains significant estimates and assumptions including, among others, revenue projections as well as selecting appropriate royalty and discount rates, which are considered a level 3 input in the fair value hierarchy.
The decrease was further attributable to a decline in LTV rates due to lower persistency. Direct Operating Cost Per Submission Direct Operating Cost per Submission is an operating metric that represents the average performance of Submissions generated during the reporting period.
Sales Per Submission Sales per Submission is an operating metric that represents the average performance of Submissions generated during the reporting period.
As of December 31, 2023, the Company had a principal amount of $110.4 million, $296.3 million and $96.1 million outstanding under the Incremental Term Loan Facility, 2021 Incremental Term Loans and 2021-2 Incremental Term Loans, respectively. The effective interest rate of the Term Loan Facilities was 13.0% at December 31, 2023.
As of December 31, 2025, the Company had a principal amount of $688.5 million outstanding under the New Term Loan Facility and no principal amounts outstanding under Term Loan Facilities. The effective interest rate of the New Term Loan Facility was 14.43% at December 31, 2025.
Technology expense Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 41,046 $ 43,302 $ (2,256) (5.2) % 5.1% 5.9% The $2.3 million, or 5.2% decrease was primarily attributable to a decrease in share-based compensation expense for technology employees.
Technology Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 34,904 $ 41,046 $ (6,142) (15.0) % 9.6% 5.1% The $6.1 million, or 15.0% decrease was primarily attributable to decreased headcount in our technology support functions.
At the option of the Borrower and prior to the New Class A Revolving Facility Termination Date, the Class A-1 Revolving Credit Facility will bear interest at either (i) ABR plus 6.50% per annum or (ii) SOFR plus 7.50% per annum.
Prior to Amendment No. 14 (as defined and further described below),at the option of the Borrower, the Existing Term Loan Facility bore interest at either (i) ABR plus 6.50% per annum or (ii) Adjusted Term SOFR plus 7.50% per annum.
GoHealth, Inc. 2024 Form 10-K 49 Interest expense Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 72,868 $ 69,472 $ 3,396 4.9 % 9.1% 9.5% The $3.4 million, or 4.9% increase was primarily attributable to an increase in interest expense related to our outstanding Revolving Credit Facilities.
Interest expense Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 87,320 $ 72,868 $ 14,452 19.8 % 24.1% 9.1% The $14.5 million, or 19.8% increase was primarily attributable to an increase in interest rates as well as an increase in our outstanding borrowings pursuant to the Company’s executed Amendment No. 14 to the Existing Credit Agreement and the Superpriority Credit Agreement.
See Note 5, “Long-Term Debt,” to the Consolidated Financial Statements in this Annual Report on Form 10-K for additional information regarding the Company’s term loans.
See Note 7, “Share-Based Compensation Plans,” to the Consolidated Financial Statements included in Item 8 to this Annual Report on Form 10-K for further discussion of share-based compensation.
Consumer care and enrollment Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 222,414 $ 209,234 $ 13,180 6.3 % 27.8% 28.5% The $13.2 million, or 6.3% increase was primarily attributable to an increased agent headcount during the 2024 AEP associated with the e-TeleQuote acquisition.
Consumer care and enrollment Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 106,045 $ 222,414 $ (116,369) (52.3) % 29.3% 27.8% The $116.4 million, or 52.3% decrease was primarily attributable to a reduced agent headcount aligning with our scale back of Medicare Advantage activities.
Operating lease impairment charges Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ — $ 2,687 $ (2,687) (100.0) % —% 0.4% As part of our continued cost savings initiatives, we are actively looking to terminate or sublease certain office spaces and call centers.
As part of the Company’s continued cost savings initiatives, the Company is actively looking to terminate or sublease certain office spaces and call centers. These actions resulted in $2.7 million in operating lease impairment charge for the twelve months ended December 31, 2023, which are included in “Indefinite and long-lived asset impairment charges” on the Consolidated Statements of Operations.
Intangible asset impairment charges Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ — $ 10,000 $ (10,000) (100.0) % —% 1.4% During the twelve months ended December 31, 2023, we recorded an impairment charge of $10.0 million to write down the carrying value of the indefinite-lived trade names intangible asset to its fair value of $73.0 million.
Indefinite and long-lived asset impairment charges Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 259,961 $ — $ 259,961 100.0 % 71.8% —% During the twelve months ended December 31, 2025, we recorded an impairment charge of 259,961 as the Company determined that the fair value of its indefinite-lived trade names and long-lived assets were impaired because of reduced forecasted cash flows under our updated business plan.
The following table presents the Direct Operating Cost per Submission for the periods presented: Direct Operating Cost Per Submission Twelve months ended Dec. 31, 2024 2023 $ Change % Change $ 578 $ 683 $ (105) (15.4) % The decrease for the twelve months ended December 31, 2024 compared to the prior year period was primarily attributable to improvements in agent productivity through enhanced training programs and investment in our technology.
The following table presents the Direct Operating Cost per Submission for the periods presented: Direct Operating Cost Per Submission Twelve months ended Dec. 31, 2025 2024 $ Change % Change $ 594 $ 578 $ 16 2.8 % The increase for the twelve months ended December 31, 2025 compared to the prior year period was primarily attributable to management’s intentional pullback of Medicare Advantage activities during 2025 partially offset by cost cutting initiatives implemented during the year.
General and administrative Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 82,116 $ 93,069 $ (10,953) (11.8) % 10.3% 12.7% The $11.0 million, or 11.8% decrease was primarily attributable to a decrease in expense related to legal fees for the Securities Class Action (as defined and discussed further in Note 12, “Commitments and Contingencies”) and a decrease in share-based compensation expense, partially offset by an increase in cost associated with the e-TeleQuote acquisition.
General and administrative Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 90,789 $ 82,116 $ 8,673 10.6 % 25.1% 10.3% The $8.7 million, or 10.6% increase was primarily attributable to an increase in expenses related to legal and professional fees.
Marketing and advertising expense Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 235,696 $ 205,042 $ 30,654 15.0 % 29.5% 27.9% The $30.7 million, or 15.0% increase was primarily attributable to an increase in our marketing and advertising spend to generate more qualified prospects, which contributed to an increase in Submissions generated by our internal agents.
Marketing and advertising Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 116,379 $ 235,696 $ (119,317) (50.6) % 32.2% 29.5% The $119.3 million, or 50.6% decrease was primarily attributable to our deliberate decision to scale back our Medicare Advantage activities and shift in focus to the launch of GoHealth Protect, partially offset by an increase in our marketing and advertising spend to generate more qualified prospects during the first quarter of 2025.
During the twelve months ended December 31, 2024, Non-Encompass BPO Services contributed no revenues. During the twelve months ended December 31, 2023 and 2022, Non-Encompass BPO Services contributed $9.3 million and $87.4 million to net revenues, respectively. During the first quarter of 2023, the Company reorganized its operations from four operating and reportable segments to one operating and reportable segment.
During the twelve months ended December 31, 2023 Non-Encompass BPO Services contributed $9.3 million to net revenues. Ownership GoHealth, Inc. is the sole managing member of GHH, LLC.
Adjusted EBITDA Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 120,319 $ 75,091 $ 45,228 60.2 % 15.1% 10.2% The $45.2 million, or 60.2% increase for the twelve months ended December 31, 2024 compared to the prior year period was primarily due to an increase in net revenues and improved operating efficiencies enabled by agent productivity, targeted marketing and enhancements in our proprietary technology.
Adjusted EBITDA Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ (35,109) $ 120,319 $ (155,428) (129.2) % (9.7)% 15.1% The $(155.4) million, or (129.2)% decrease for the twelve months ended December 31, 2025 compared to the prior year period was primarily due to a decrease in net revenues driven by management’s intentional pullback of Medicare Advantage activities during 2025 partially offset by cost cutting initiatives implemented during the year.
“Description of Business and Significant Accounting Policies,” to the Consolidated Financial Statements included in Item 8 to this Annual Report on Form 10-K. Liquidity and Capital Resources GoHealth, Inc. 2024 Form 10-K 53 Overview Our liquidity needs primarily include working capital and debt service requirements. At December 31, 2024, cash and cash equivalents totaled $40.9 million.
Recent Accounting Pronouncements For a discussion of new accounting pronouncements recently adopted, see Note 1. “Description of Business and Significant Accounting Policies,” to the Consolidated Financial Statements included in Item 8 to this Annual Report on Form 10-K.
The Amendment and Restatement Agreement, which amended and restated the Credit Agreement, provided for, among other items, an additional revolving credit facility with a commitment amount of $35.0 million (the “Class A-1 Revolving Credit Facility”), which will be made available to the Borrower upon the termination of the New Class A Revolving Commitments on or prior to June 30, 2025 (the “New Class A Revolving Facility Termination Date”).
The Class A-1 Revolving Credit Facility was to be made available to the Borrower upon the termination of the Class A Revolving Credit Facility on or prior to June 30, 2025 (which was then further extended pursuant to Amendment No. 13 and Amendment No. 14). Following the entry into Amendment No. 14, the Class A-1 Revolving Credit Facility was terminated.
Amortization of intangible assets Twelve months ended Dec. 31, % of Net Revenues 2024 2023 $ Change % Change 2024 2023 $ 94,057 $ 94,057 $ — — % 11.8% 12.8% Amortization of intangible assets expense was $94.1 million for both the twelve months ended December 31, 2024 and 2023, and relates to the amortization of developed technology and customer relationships.
Amortization of intangible assets Twelve months ended Dec. 31, % of Net Revenues 2025 2024 $ Change % Change 2025 2024 $ 70,542 $ 94,057 $ (23,515) (25.0) % 19.5% 11.8% Amortization of intangible assets expense decreased driven by the impairment of intangible assets during 2025.
The decrease in non-agency revenue compared to the prior year is reflective of a shift from non-agency to agency revenue as a result of changing health plan partner mix within the non-agency channel.
The guaranteed acceptance life insurance product produces lower revenues on a per-submission basis compared to Medicare products. The decrease was further attributable to a shift from non-agency to agency revenue as a result of changing carrier mix within the non-agency channel.
The Company had no amounts outstanding under the Class A Revolving Credit Facilities and Class B Revolving Credit Facilities as of December 31, 2023. The Class A Revolving Credit Facilities and Class B Revolving Credit Facilities had a remaining capacity of $200.0 million in the aggregate as of December 31, 2023.
The Class A Revolving Credit Facilities and Class B Revolving Credit Facilities had a remaining capacity of $58.5 in the aggregate as of December 31, 2024. Superpriority Credit Agreement On August 6, 2025 (the “Closing Date”), the Borrower entered into the Superpriority Senior Secured Credit Agreement (the “Superpriority Credit Agreement”).
There are additional estimates and assumptions used to arrive at estimated future cash flows, including discount rate, downtime, abatement and commissions. As a result of the impairment testing over certain operating lease ROU assets, the Company recorded operating lease impairment charges of $2.7 million and $25.3 million for the twelve months ended December 31, 2023 and 2022, respectively.
There are additional estimates and assumptions used to arrive at estimated future cash flows, including discount rate, downtime, abatement and commissions. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair value.
(9) Represents employee termination benefits and other associated costs related to restructuring activities, as described in Note 14, “Restructuring Costs” of the Notes to Consolidated Financial Statements. (10) Represents an indefinite-lived intangible asset impairment charge for the twelve months ended December 31, 2023.
(7) Represents expense related to the measurement of our TRA obligation. (8) Represents indefinite-lived intangible asset, definite-lived intangible asset, capitalized software and other long-lived asset impairment charge for the twelve months ended December 31, 2025.